Certified by Founder Lodge
CellCentric
United Kingdom - Cambridge
START UP
1 Disclosed Funding Rounds $25,000,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.
p300/CBP are twin (paralogue) acetyl transferases
Pfizer
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
Sigma360 | $17,000,000 | (Mar 11, 2026)
Unreasonable Labs | $13,500,000 | (Mar 11, 2026)
PactFi | $25,000,000 | (Mar 11, 2026)
Lux Aeterna | $10,000,000 | (Mar 11, 2026)
Axiom Trust Company | $11,800,000 | (Mar 11, 2026)
